University of Vermont

The College of Arts and Sciences

Department of Psychological Science

Stacey Sigmon

Human Behavioral Pharmacology

Stacey Sigmon

Stacey Sigmon
Research Associate Professor of Psychology
Research Associate Professor of Psychiatry

Education
  • B.A. University of North Carolina at Chapel Hill, 1995
  • M.A. University of Vermont, 1999
  • Ph.D. University of Vermont, 2002
  • NIH Postdoctoral Fellowship at Johns Hopkins University School of Medicine
  • C.V. (PDF)
Email: stacey.sigmon@uvm.edu
Phone: (802) 656-8714
Room: FAHC-UHC Room 1415

Directorships

Director, The Chittenden Clinic

Duties

Faculty, Substance Abuse Treatment Center

Faculty, Human Behavioral Pharmacology Laboratory

Faculty, Behavioral Pharmacology of Drug Dependence Training Program

Areas

Behavioral and pharmacological treatment of opioid dependence; Novel formulations of pharmacotherapies for opioid dependence; Smoking cessation among opioid-dependent patients using a behavioral approach; Laboratory models for understanding the interactions between stimulant medications, including nicotine, cocaine, d-amphetamine and methylphenidate; Behavioral treatments of substance use/abuse among individuals with serious mental illness.

Facilities

Vermont Center on Behavior and Health: The Vermont Center on Behavior and Health (VCBH) is an interdisciplinary center of research excellence committed to investigating relationships between personal behavior patterns (i.e., lifestyle) and risk for chronic disease and premature death.

Human Behavioral Pharmacology Laboratory (HBPL): This facility of 6,000 sq. ft., is located adjacent to the University of Vermont (UVM) campus in Burlington and is the site for laboratory research in drug self-administration, drug discrimination, and the direct effects of drugs and for treatment studies for smoking cessation.

Substance Abuse Treatment Center (SATC): This facility of 2,900 sq. ft., is also located adjacent to the UVM campus, and is our site for the development and testing of scientifically-based behavioral and pharmacological treatments for cocaine and opioid dependence as well as smoking cessation for pregnant women. For addtional information on the Substance Abuse Treatment Center3.

Representative Publications

  • Sigmon, S.C., Ochalek, T., Meyer, A., Hruska, B., Heil, S.H., Badger, G.J., Rose, G., Brooklyn, J.R., Schwartz, R.P., Moore, B.A. & Higgins, S.T. (2016). Interim buprenorphine vs. waiting list for opioid dependence. The New England Journal of Medicine, 375(25), 2504-2505.
  • Sigmon, S.C., Miller, M., Meyer, A.C., Saulsgiver, K., Badger, G.J., Heil, S.H. & Higgins, S.T. (2016). Financial incentives to promote extended smoking abstinence in opioid-maintained patients: A randomized trial. Addiction, 111(5), 903-912.
  • Sigmon, S.C. & Bigelow, G.E. (2016). FDA approval of sustained-release buprenorphine for treatment of opioid dependence: Realizing its potential. Addiction. doi: 10.1111/add.13539
  • Sigmon, S.C. (2016). Additive burdens of malnutrition, poverty and substance abuse. The Lancet, 388, 1879-1880.
  • Higgins, S.T., Heil, S.H., Sigmon, S.C., Tidey, J.W., Gaalema, D.E., Stitzer, M.L., Durand, H., Bunn, J.Y., Priest, J.S., Arger, C.A., Miller, M.E., Bergeria, C.L., Davis, D.R., Streck, J.M., Zvorsky, I., Redner, R., Vandrey, R. & Pacek, L.R. (2016). Response to varying the nicotine content level of cigarettes in vulnerable populations: An initial experimental examination of acute effects. Psychopharmacology, doi:10.1007/s00213-016-4438-z.
  • Sigmon, S.C. (2015). The untapped potential of office-based buprenorphine treatment. JAMA Psychiatry, 72(4), 395-396.
  • Sigmon, S.C. (2014). Access to treatment for opioid dependence in rural America: Challenges and future directions. JAMA Psychiatry, 71(4), 359-60.
  • Sigmon, S.C., Dunn, K., Saulsgiver, K., Patrick, M., Badger, G.J., Heil, S.H., Brooklyn, J., & Higgins, S.T. (2013). A randomized, double-blind evaluation of buprenorphine taper duration in primary prescription opioid abusers. JAMA Psychiatry, 70(12), 1347-1354.
  • Rosenthal, R.N., Ling, W., Casadonte, P., Vocci, F., Bailey, G.L., Kampman, K., Patkar, A., Chavoustie, S., Blasey, C., Sigmon, S.C., & Beebe, K.L. (2013). Buprenorphine implants for treatment of opioid dependence: Randomized comparison to placebo and sublingual buprenorphine/naloxone. Addiction, 108(12), 2141-2149.

Faculty and Staff Directory